iVeena received $2 million in grant funding to advance IVMED-80, an FDA-designated orphan drug eye drop for the treatment of keratoconus, a rare degenerative corneal disorder.
iVeena received $2 million in grant funding to advance IVMED-80, an FDA-designated orphan drug eye drop for the treatment of keratoconus, a rare degenerative corneal disorder.